CRIS Current Research Information System

GUGLIOTTA, GABRIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.487
AS - Asia 6.142
EU - Europa 4.108
SA - Sud America 383
Continente sconosciuto - Info sul continente non disponibili 340
AF - Africa 337
OC - Oceania 14
Totale 17.811
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.371
VN - Vietnam 1.711
SG - Singapore 1.616
CN - Cina 1.514
GB - Regno Unito 1.165
IT - Italia 615
DE - Germania 483
SE - Svezia 476
HK - Hong Kong 362
NL - Olanda 299
BR - Brasile 276
FR - Francia 260
IN - India 257
RU - Federazione Russa 218
KR - Corea 144
BD - Bangladesh 142
IE - Irlanda 141
UA - Ucraina 110
JP - Giappone 107
ZA - Sudafrica 95
TG - Togo 82
EE - Estonia 72
FI - Finlandia 62
CA - Canada 59
CI - Costa d'Avorio 56
BG - Bulgaria 51
JO - Giordania 51
NG - Nigeria 38
AR - Argentina 36
PH - Filippine 34
CH - Svizzera 33
ID - Indonesia 30
TH - Thailandia 28
IQ - Iraq 27
AT - Austria 26
BE - Belgio 25
SC - Seychelles 23
PL - Polonia 19
EC - Ecuador 18
MX - Messico 18
IR - Iran 17
TW - Taiwan 17
TR - Turchia 15
PK - Pakistan 14
AU - Australia 13
ES - Italia 13
CL - Cile 12
CO - Colombia 11
VE - Venezuela 11
UZ - Uzbekistan 9
JM - Giamaica 8
CR - Costa Rica 7
IL - Israele 7
MA - Marocco 7
PE - Perù 7
SA - Arabia Saudita 7
HN - Honduras 6
LB - Libano 6
MY - Malesia 6
PY - Paraguay 6
TN - Tunisia 6
CZ - Repubblica Ceca 5
ET - Etiopia 5
GR - Grecia 5
GT - Guatemala 5
KE - Kenya 5
RO - Romania 5
AE - Emirati Arabi Uniti 4
DK - Danimarca 4
EG - Egitto 4
LT - Lituania 4
LY - Libia 4
NO - Norvegia 4
UY - Uruguay 4
AL - Albania 3
NP - Nepal 3
PR - Porto Rico 3
AZ - Azerbaigian 2
DZ - Algeria 2
GE - Georgia 2
GM - Gambi 2
LA - Repubblica Popolare Democratica del Laos 2
LC - Santa Lucia 2
LV - Lettonia 2
MU - Mauritius 2
PS - Palestinian Territory 2
PT - Portogallo 2
RS - Serbia 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
ZM - Zambia 2
AO - Angola 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
CY - Cipro 1
EU - Europa 1
GP - Guadalupe 1
HT - Haiti 1
Totale 17.460
Salva come PNG Salva come JPEG
Città #
Singapore 1.153
Southend 1.072
Ashburn 733
Fairfield 606
Chandler 473
Ho Chi Minh City 397
San Jose 378
Hanoi 367
Hong Kong 338
Woodbridge 298
Wilmington 297
Houston 292
Seattle 278
Hefei 277
Beijing 249
Dong Ket 226
Cambridge 220
Princeton 201
Ann Arbor 170
Dublin 141
Boardman 136
Seoul 125
Bologna 124
Santa Clara 114
Lauterbourg 108
Council Bluffs 105
Nanjing 102
Tokyo 87
New York 84
Westminster 83
Lomé 82
Los Angeles 82
Padova 71
Berlin 64
Dallas 63
Abidjan 56
Buffalo 54
Haiphong 54
Milan 54
Helsinki 52
Da Nang 51
Sofia 51
Jinan 50
Amman 48
Chicago 46
Shenyang 45
Jacksonville 43
Redondo Beach 42
Frankfurt am Main 41
Turin 38
Abeokuta 37
Changsha 37
São Paulo 36
Saint Petersburg 33
Bengaluru 31
Shanghai 30
Nanchang 28
Rome 28
San Diego 28
Tianjin 28
Bern 27
Biên Hòa 26
Guangzhou 25
Medford 25
Brussels 24
Falls Church 24
Redmond 24
Jiaxing 23
Munich 22
Nuremberg 22
The Dalles 22
Zhengzhou 22
Des Moines 21
Hebei 21
Orem 21
Bremen 19
London 18
Mountain View 18
Norwalk 18
Phoenix 17
Chengdu 16
Hangzhou 16
Montreal 16
Toronto 16
Baghdad 15
Boston 15
Dearborn 15
Warsaw 15
Can Tho 14
Hải Dương 14
Ninh Bình 14
Bắc Ninh 13
Falkenstein 13
Ha Long 13
Jakarta 13
Taizhou 13
Brooklyn 12
Denver 12
Haikou 12
Ningbo 12
Totale 11.355
Salva come PNG Salva come JPEG
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 391
IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia 388
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 278
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 257
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 244
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 238
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib 230
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 230
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 222
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 222
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 220
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 217
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 217
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 210
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 207
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 203
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview 203
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 202
Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms 201
Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study 201
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 194
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 193
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 191
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients 191
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 188
A review of the European LeukemiaNet recommendations for the management of CML 187
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 187
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study 184
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 178
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 176
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia 172
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 172
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 171
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 171
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 171
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 169
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study 168
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 167
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 166
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 166
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 164
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. 163
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 163
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 161
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors 159
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 159
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey 159
Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. 158
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 156
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. 156
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 155
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. 152
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 151
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia 150
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 150
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib 149
Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom? 147
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. 146
Frontline Treatment of Philadelphia Positive Chronic Myeloid Leukemia with Sequential Administration of Nilotinib 400 Mg Twice Daily and Imatinib 400 Mg Once Daily: a Phase 2 Multicentric Study 146
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 144
Resistance to second-line tyrosine kinase inhibitor treatment in imatinib-resistant Philadelphia-positive leukemia patients can be anticipated by ultra-deep sequencing of the BCR-ABL kinase domain using Roche 454 technology 144
Diagnosis and classification of the risk 143
Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy 143
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 143
High Sensitivity Mutation Screening and Clonal Analysis Allowed by Ultra-Deep Amplicon Sequencing Uncover the Complexity of Bcr-Abl Mutation Status in Patients Treated with Tyrosine Kinase Inhibitors 142
Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia 142
Validation of the New European LeukemiaNet (ELN) Recommendations for Bcr-Abl Kinase Domain Mutation Analysis In Chronic Myeloid Leukemia: An Analysis of the GIMEMA CML Working Party Studies 142
Ultrasound-guided core needle biopsy of nodular lesions of the spleen in hematology clinical practice 139
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. 139
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice 138
Positive Selection and Transplantation of Autologous Highly Purified CD133+ Stem Cells in Resistant/Relapsed Chronic Lymphocytic Leukemia Patients Results in Rapid Hematopoietic Reconstitution without an Adequate Leukemic Cell Purging 138
Essential role of lyn in fibrosis 137
Efficacy and safety of nilotinib as frontline treatment in elderly (> 65 years) chronic myeloid leukemia patients outside clinical trials 133
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. 133
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP 131
First-Line Treatment of Newly Diagnosed Elderly Patients with Chronic Myeloid Leukemia: Current and Emerging Strategies 130
EARLY PREDICTORS OF PROGRESSION TO ACCELERATED-BLASTIC PHASE IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED FRONTLINE WITH NILOTINIB-BASED REGIMENS 128
Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients 128
Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia 127
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 127
F317L BCR-ABL1 kinase domain mutation associated with a sustained major molecular response in a CML patient on dasatinib 125
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia 123
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 123
Safety profiles of first-line TKIS and managing adverse effects 122
Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain 121
Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study 121
SARS-CoV-2 infection does not affect the outcome of patients with relapsed/refractory large B-cell lymphoma treated with CAR T-cell therapy 120
Differences among young adults, adults and elderly chronic myeloid leukemia patients 120
Current treatment approaches in CML. 119
NILOTINIB 400 MG BID IN EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA: BEYOND 4 YEARS RESULTS REMAIN STABLE - THE GIMEMA CML WP TRIAL CML0307 117
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase 117
Deep sequencing of the bcr-abl kinase domain reveals a high frequency of bcr-abl35-ins insertion/truncation mutation in chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia patients 116
Physician’s guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML 115
CML-184 A Novel Droplet Digital PCR Strategy for Rapid and Sensitive Detection of BCR::ABL1 Kinase Domain Mutations Conferring Resistance to Second-Generation Tyrosine Kinase Inhibitors 114
EUTOS SCORE IS PREDICTIVE FOR SURVIVAL AND OUTCOME IN PATIENTS WITH EARLY CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TREATED WITH NILOTINIB-BASED REGIMENS 112
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report 112
Chronic myeloid leukemia. Drug selection in first-line therapy and beyond 108
Thyrosin kinase inhibitors: nilotinib 105
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure 100
Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools 95
Totale 16.463
Salva come PNG Salva come JPEG
Categoria #
all - tutte 47.624
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 47.624
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.521 0 57 137 140 170 99 27 97 83 103 286 322
2022/20231.961 198 299 107 240 156 140 87 122 341 35 159 77
2023/2024507 27 83 36 55 47 116 25 19 23 32 18 26
2024/20252.352 66 357 205 164 267 106 148 63 32 366 119 459
2025/20266.102 696 667 532 445 569 288 556 278 1.132 468 261 210
2026/2027480 253 227 0 0 0 0 0 0 0 0 0 0
Totale 17.811